Clinical Trial

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2016-12-28; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2017-04-06
Trial Details
NCT Number NCT03007030
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Enrollment 55 participants
Start Date 2017-04-05
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15